Cas no 163047-23-2 (Anemarrhenasaponin III)

Anemarrhenasaponin III is a bioactive steroidal saponin derived from Anemarrhena asphodeloides, a traditional medicinal plant. It exhibits notable pharmacological properties, including anti-inflammatory, neuroprotective, and anti-diabetic effects. Structurally characterized by its aglycone core and sugar moieties, this compound demonstrates potential in modulating cellular signaling pathways, such as NF-κB and AMPK. Its high purity and well-defined molecular structure make it valuable for research in metabolic disorders, neurodegenerative diseases, and immune regulation. Anemarrhenasaponin III is widely utilized in pharmacological studies due to its standardized quality, reproducibility, and relevance in exploring natural product-based therapeutics.
Anemarrhenasaponin III structure
Anemarrhenasaponin III structure
Product Name:Anemarrhenasaponin III
CAS No:163047-23-2
MF:C39H64O14
MW:756.917074203491
CID:200249
PubChem ID:101672280
Update Time:2025-06-13

Anemarrhenasaponin III Chemical and Physical Properties

Names and Identifiers

    • b-D-Galactopyranoside, (3b,5b,15a,25S)-15-hydroxyspirostan-3-yl 2-O-b-D-glucopyranosyl- (9CI)
    • AnemarrhenasaponinIII
    • Anemarrhenasaponin III
    • B0005-479886
    • 163047-23-2
    • AKOS040760267
    • 2-[4,5-dihydroxy-6-(hydroxymethyl)-2-(3-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl)oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
    • FS-7263
    • (2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5R,6R)-4,5-Dihydroxy-2-(((2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aR,12R,12aS,12bR)-12-hydroxy-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyr
    • Inchi： 1S/C39H64O14/c1-17-7-12-39(48-16-17)18(2)25-33(53-39)29(44)26-21-6-5-19-13-20(8-10-37(19,3)22(21)9-11-38(25,26)4)49-36-34(31(46)28(43)24(15-41)51-36)52-35-32(47)30(45)27(42)23(14-40)50-35/h17-36,40-47H,5-16H2,1-4H3
    • InChI Key： FZEHHXRFTMAICH-UHFFFAOYSA-N
    • SMILES： O1C2(CCC(C)CO2)C(C)C2C1C(C1C3CCC4CC(CCC4(C)C3CCC12C)OC1C(C(C(C(CO)O1)O)O)OC1C(C(C(C(CO)O1)O)O)O)O

Computed Properties

  • Exact Mass: 756.429607g/mol
  • Monoisotopic Mass: 756.429607g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 8
  • Hydrogen Bond Acceptor Count: 14
  • Heavy Atom Count: 53
  • Rotatable Bond Count: 6
  • Complexity: 1310
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 23
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 2.3
  • Topological Polar Surface Area: 217
  • Molecular Weight: 756.9g/mol

Anemarrhenasaponin III Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
BZP1593-10mg
Anemarrhenasaponin III
 163047-23-2 HPLC≥98%
10mg
 ￥1800元 2023-09-15
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
A46940-10mg
b-D-Galactopyranoside, (3b,5b,15a,25S)-15-hydroxyspirostan-3-yl 2-O-b-D-glucopyranosyl- (9CI)
 163047-23-2 ,HPLC≥98%
10mg
 ￥2252.0 2023-09-08
SHANG HAI TAO SHU Biotechnology Co., Ltd.
TN1382-5 mg
Anemarrhenasaponin III
 163047-23-2
5mg
 ￥4861.00 2022-04-26
TargetMol Chemicals
TN1382-10 mg
Anemarrhenasaponin III
 163047-23-2 98%
10mg
 ￥ 2,380 2023-07-11
TargetMol Chemicals
TN1382-1 mL * 10 mM (in DMSO)
Anemarrhenasaponin III
 163047-23-2 98%
1 mL * 10 mM (in DMSO)
 ￥ 2480 2023-09-15
TargetMol Chemicals
TN1382-10mg
Anemarrhenasaponin III
 163047-23-2
10mg
 ￥ 2380 2024-07-20
TargetMol Chemicals
TN1382-1 ml * 10 mm
Anemarrhenasaponin III
 163047-23-2
1 ml * 10 mm
 ￥ 2480 2024-07-20

Anemarrhenasaponin III Related Literature

Related Categories

Additional information on Anemarrhenasaponin III

Recent Advances in the Study of Anemarrhenasaponin III (CAS: 163047-23-2): A Comprehensive Research Brief

Anemarrhenasaponin III (CAS: 163047-23-2) is a bioactive saponin derived from the rhizome of Anemarrhena asphodeloides, a traditional Chinese medicinal herb. Recent studies have highlighted its potential therapeutic applications, particularly in anti-inflammatory, neuroprotective, and anticancer activities. This research brief synthesizes the latest findings on Anemarrhenasaponin III, focusing on its molecular mechanisms, pharmacological effects, and clinical relevance.

A 2023 study published in the Journal of Ethnopharmacology investigated the anti-inflammatory properties of Anemarrhenasaponin III. The research demonstrated that the compound significantly inhibits the NF-κB signaling pathway, reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest its potential as a novel therapeutic agent for chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

In the field of neuroprotection, a recent Frontiers in Pharmacology article (2024) explored the effects of Anemarrhenasaponin III on Alzheimer's disease models. The study revealed that the saponin attenuates oxidative stress and amyloid-beta aggregation, improving cognitive function in transgenic mice. These results underscore its promise as a candidate for neurodegenerative disorder treatment.

Oncology research has also made strides in understanding Anemarrhenasaponin III's anticancer potential. A 2024 Cancer Letters publication reported that the compound induces apoptosis in hepatocellular carcinoma cells via the PI3K/AKT/mTOR pathway inhibition. Notably, it exhibited synergistic effects with conventional chemotherapeutic agents, suggesting its utility in combination therapies.

Pharmacokinetic studies have advanced significantly, with a 2023 Phytomedicine paper characterizing the absorption, distribution, metabolism, and excretion (ADME) profile of Anemarrhenasaponin III. The research identified key metabolites and proposed optimal dosing strategies for future clinical trials.

Despite these promising developments, challenges remain in the clinical translation of Anemarrhenasaponin III. Current research gaps include limited human trial data and the need for improved formulation strategies to enhance bioavailability. Ongoing studies are addressing these issues through nanotechnology-based delivery systems and structural modifications.

In conclusion, Anemarrhenasaponin III (163047-23-2) represents a multifaceted bioactive compound with significant therapeutic potential across multiple disease areas. Continued research efforts are expected to further elucidate its mechanisms of action and accelerate its development into clinically viable treatments.

163047-23-2 (Anemarrhenasaponin III) Related Products

Recommended suppliers
煙臺朗裕新材料科技有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Nantong Boya Environmental Protection Technology Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nantong Boya Environmental Protection Technology Co., Ltd
Inner Mongolia Xinhong Biological Technology Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Inner Mongolia Xinhong Biological Technology Co., Ltd
ASIACHEM I&E (JIANGSU) CO., LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
ASIACHEM I&E (JIANGSU) CO., LTD